Deepen cooperation!

At present, China's pharmaceutical market has steadily ranked as the world's second largest pharmaceutical market, and will continue to grow in the future
.

With the continuous in-depth advancement of strategies such as "Healthy China 2030", the potential of China's pharmaceutical market is expected to be further released

The vibrant and energetic Chinese market is also attracting the attention of more and more multinational pharmaceutical companies
.

They continue to increase their investment in China, try their best to meet the unmet medical needs of Chinese patients, and at the same time accelerate the pace of their innovative products entering the market, ensure the demand for clinical treatment, and expand the availability of drugs

Opportunities and challenges coexist.
On the one hand, with the implementation of a series of Chinese pharmaceutical policies, more and more foreign innovative products can enter the Chinese market faster and serve more patients; on the other hand, the original pharmaceutical industry structure is also With drastic changes, the reshuffle of the Chinese pharmaceutical market is accelerating, and it is transforming into an efficiency revolution
.

Before the huge unmet medical needs, whether it is a multinational pharmaceutical company or a domestic pharmaceutical company, efficiency synergy and win-win cooperation among enterprises have become more and more important

In this context, the cooperation between domestic and foreign pharmaceutical companies has become more frequent and close
.

Following the successful commercialization of Harle® retail channels, today Astellas has once again in-depth cooperation with Baiyang Pharmaceutical, which is expected to make another breakthrough in the commercialization of the innovative drug Betanley®

The "Brand Expressway" is working hard again!

The "Brand Expressway" is working hard again!

On November 9, 2021, Astellas and Baiyang Pharmaceutical signed a cooperation agreement in Qingdao.
The promotion and operation of Solinasin acid tablets) and Haro® (tamsulosin hydrochloride sustained-release capsules) in mainland China reached a deepening cooperation agreement
.

Signing ceremony site

According to the agreement, Baiyang Pharmaceutical will obtain the promotion and service rights of Betani® and Wexikang® in mainland China
.

At the same time, following Baiyang Pharmaceutical's acquisition of Haro®'s retail channel operation rights in mainland China in 2019, this agreement complements other market cooperation in addition to retail channels

It is worth noting that Betani® and Wexikang®, which are newly launched on the "brand highway" of Baiyang Pharmaceutical, are special drugs for the treatment of overactive bladder (OAB)
.

Weixikang® is an M receptor antagonist developed by Astellas.
It is suitable for OAB symptoms such as urinary urgency, frequent urination, and urgency urinary incontinence.
It is currently listed in the National Medical Insurance Catalog (Category B) drug; Betantyl® is the lead A β3 receptor agonist approved by the FDA for the treatment of OAB was officially launched in China in 2018.
It has high safety and fills the gap of β3 receptor agonists in the treatment of OAB in China
.

In 2020, the drug was included in the National Medical Insurance List (Class B) drug

Relevant data show that the prevalence of OAB among people over 40 years old in China is 11.
3%, and the incidence increases with age.
The intensified population aging will also cause the number of patients to continue to increase
.

However, China’s OAB presents the severe challenge of "high prevalence and low consultation rate", and treatment cannot be ignored

The main treatment methods for OAB include behavioral therapy, biofeedback therapy, and drug therapy.
Among them, drug therapy is the second-line treatment method, and the commonly used clinical drugs are new muscarinic receptor (M receptor) antagonists or β3 receptor agonists
.

This cooperation between the two parties will not only deepen the commercial cooperation in innovative drugs, but also further enhance the availability of high-quality drugs in the urinary field, bringing more treatment options to Chinese patients with urinary diseases
.

Combining advantages to benefit more patients

Combining advantages to benefit more patients

As a large multinational pharmaceutical company, Astellas currently has operations in more than 70 countries and regions around the world
.

In 1994, Astellas entered China and was committed to providing high-quality innovative drugs and services to the Chinese public to improve the health and well-being of Chinese society

With years of experience in the Chinese market, Astellas is keenly aware of the current trend of change in the domestic pharmaceutical market, and is the first to make a transition
.

As early as 2019, Astellas reached a cooperation agreement with Baiyang Pharmaceutical, granting the brand operation of Harle® to Baiyang Pharmaceutical in China
.
Relying on Baiyang Pharmaceutical's professional brand operation capabilities, Harle®'s retail market share has been significantly increased, and it has successfully released value in retail channels
.
In addition, the two parties are also cooperating on Philippine®, innovative drug XOSPATA® and other products to provide health services for Chinese patients in multiple disease areas
.

According to Sina Pharmaceuticals, Astellas recently announced the completion of the company’s strategic layout upgrade, the establishment of the Greater China headquarters in Beijing, and the establishment of Astellas on the basis of the original Astellas Pharmaceuticals (China) Co.
, Ltd.
China) Investment Co.
, Ltd.
and Beijing Astellas Pharmaceutical Co.
, Ltd.
jointly promote Astellas's strong development in the Chinese market and help achieve the goal of Healthy China 2030
.

Based on the good foundation of cooperation between the two parties, this time the promotion and service rights of Betani®, Vixikang®, and Haro® have been handed over to Baiyang Pharmaceuticals.
It can be seen that Astellas’s ability to commercialize Baiyang Pharmaceuticals brands Recognized
.

Binkou Yang, General Manager of Astellas Greater China Business District

Mr.
Binkouyo, general manager of Astellas Greater China Business District, said that the company hopes to transform scientific progress into the value of patients and contribute to the health of people around the world by providing innovative and reliable pharmaceutical products
.
Baiyang Pharmaceutical is an important partner of Astellas in China.
The two parties have a solid foundation for cooperation.
This time they join hands again, hoping to continue to rely on Baiyang Pharmaceutical's brand commercialization platform to benefit more patients
.
At the same time, this cooperation is also an important measure for Astellas to continuously optimize and upgrade its strategic layout in Greater China, continue to increase the size of the Chinese market, and ultimately benefit Chinese patients
.

Fu Gang, Chairman of Baiyang Pharmaceutical

Regarding this cooperation, Mr.
Fu Gang, the chairman of Baiyang Pharmaceutical, said that based on years of operating practices, Baiyang Pharmaceutical has formed a mature brand operation management model, and through the formulation of precise operating strategies for brands in different life cycles, effective resource allocation , So that products can be quickly integrated into application scenarios, and fully release brand value
.
In line with the patient-centered concept, Baiyang Medicine will work with Astellas to bring patients an overall solution for disease treatment
.
After 16 years of cultivating the industry, Baiyang Pharmaceutical has a strong marketing network.
Through the three core capabilities of category insight and brand operation, full data platform customer management, and long-term operation mechanism, it provides upstream industrial enterprises with omni-channel commercialization solutions to help Good products and services quickly enter the application scenarios
.
Relying on a professional commercialization platform, in recent years, Baiyang Pharmaceutical has successively reached cooperative relationships with leading companies such as Roche Pharmaceuticals, Jet Belling, Xi'an Janssen, Takeda, and 3SBio
.